Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.

Abstract excerpt

Breast and prostate cancers are generally considered immunologically 'cold' tumors due to multiple mechanisms rendering them unresponsive to immune checkpoint blockade therapies. With little success in garnering positive outcomes in modern immunotherapeutic clinical trials, it is prudent to re-examine the role of immunogenic neoantigens in these cold tumors. Gene fusions are driver mutations in hormone-driven...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antigens, Neoplasm
• Share to Gene Fusion
• Share to Immunotherapy